Sugi Predict

Sugi Predict / Compounds / SCHEMBL1065393

SCHEMBL1065393

SCHEMBL1065393

O=C(CCCCCC(=O)Nc1ccccc1)Nc1ccccc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 19/20 0.85
▸ HDAC1 Q13547 19/20 0.85
▸ HDAC11 Q96DB2 19/20 0.85
▸ HDAC8 Q9BY41 19/20 0.85
▸ HDAC6 Q9UBN7 19/20 0.85
▸ HDAC5 Q9UQL6 19/20 0.85
▸ HDAC7 Q8WUI4 18/20 0.85
▸ HDAC9 Q9UKV0 18/20 0.85
▸ HDAC3 O15379 18/20 0.85
▸ HDAC2 Q92769 18/20 0.85
▸ HDAC10 Q969S8 18/20 0.85
▸ NCOR1 O75376 2/20 0.85
▸ NCOR2 Q9Y618 2/20 0.85
▸ KDM4E B2RXH2 1/20 0.85
▸ BRD4 O60885 1/20 0.85
▸ NR1I2 O75469 1/20 0.85
▸ EGFR P00533 1/20 0.85
▸ CYP3A4 P08684 1/20 0.85
▸ LTA4H P09960 1/20 0.85
▸ NR0B1 P51843 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6665592 1.00 HDAC4 (0.85) HDAC4HDAC1HDAC11HDAC8HDAC6
SCHEMBL137348 1.00 HDAC4 (0.85) HDAC4HDAC1HDAC11HDAC8HDAC6
SCHEMBL6669511 1.00 HDAC4 (0.85) HDAC4HDAC1HDAC11HDAC8HDAC6
SCHEMBL517309 0.98 HDAC4 (0.81) HDAC4HDAC1HDAC11HDAC8HDAC6
Hydroxyamine SCHEMBL1268824 0.96 HDAC6 (0.79) HDAC4HDAC1HDAC11HDAC8HDAC6
SCHEMBL1064861 0.94 HDAC4 (0.77) HDAC4HDAC1HDAC11HDAC8HDAC6
SCHEMBL312344 0.94 HDAC4 (0.77) HDAC4HDAC1HDAC11HDAC8HDAC6
SCHEMBL6296181 0.93 HDAC4 (0.75) HDAC4HDAC1HDAC11HDAC8HDAC6
SCHEMBL23055010 0.92 HDAC1 (1.00) HDAC4HDAC1HDAC11HDAC8HDAC6
SCHEMBL4403514 0.92 HDAC8 (0.74) HDAC4HDAC1HDAC11HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040731-A2 SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER Merrion Research III Limited (IE) 2009-04-01 — — EP claimed
WO-2007146234-A2 SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER MERRION RESEARCH II LIMITED (IE) 2007-12-21 — — WO claimed
US-11116849-B2 Hydrogel-linked prodrugs releasing tagged drugs ASCENDIS PHARMA A/S (DK) 2021-09-14 — — US disclosed
US-10653795-B2 — — 2020-05-19 — — US disclosed
WO-2018163131-A1 RELEASABLE CONJUGATES QUIAPEG PHARMACEUTICALS AB (SE) 2018-09-13 — — WO disclosed
US-9957225-B2 Treatment of friedreich's ataxia using histone deacetylase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2018-05-01 — — US disclosed
US-9957225-B2 Treatment of friedreich's ataxia using histone deacetylase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2018-05-01 — — US disclosed
US-9957225-B2 Treatment of friedreich's ataxia using histone deacetylase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2018-05-01 — — US disclosed
CN-105688218-A Solid pharmaceutical composition with enhancers and methods of preparing thereof 诺和诺德股份有限公司 2016-06-22 — — CN disclosed
EP-3006424-A1 HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES The Scripps Research Institute (US) 2016-04-13 — — EP disclosed
CN-102970979-B Solid pharmaceutical composition with enhancer and preparation method thereof MERRION RESEARCH III LTD. (IE) 2016-04-13 — — CN disclosed
US-20070219244-A1 Histone deacetylase inhibitors as therapeutics for neurological diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2007-09-20 — — US disclosed
US-20070219244-A1 Histone deacetylase inhibitors as therapeutics for neurological diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2007-09-20 — — US disclosed
WO-2007058927-A1 HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2007-05-24 — — WO disclosed
WO-2007058927-A1 HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2007-05-24 — — WO disclosed
EP-0962489-B1 Crystalline polypropylene resin composition and amide compounds NEW JAPAN CHEM CO LTD (JP) 2004-09-15 — — EP disclosed
US-6235823-B1 CRYSTALLINE POLYPROPLYLENE RESIN AND A BETA-NUCLEATING AGENT, THE BETA-NUCLEATING AGENT BEING A DIAMIDE COMPOUND. NEW JAPAN CHEMICAL CO., LTD. (JP) 2001-05-22 — — US disclosed
EP-0557721-B1 Polypropylene moulded articles with increased -crystal content and bisamides as -nucleating agents. NEW JAPAN CHEM CO LTD (JP) 2000-10-04 — — EP disclosed
EP-0962489-A2 Crystalline polypropylene resin composition and amide compounds NEW JAPAN CHEMICAL CO.,LTD. (JP) 1999-12-08 — — EP disclosed
EP-0557721-A2 Crystalline polypropylene resin composition and amide compounds NEW JAPAN CHEMICAL CO.,LTD. (JP) 1993-09-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10653795-B2 — PTMS, MSN, CD44 HDAC4 879/4885HDAC1 691/4885HDAC11 1104/4885
US-20070219244-A1 Histone deacetylase inhibitors as therapeutics for neurological diseases HDAC5, HDAC1, HDAC6 HDAC4 5/4885HDAC1 2/4885HDAC11 7/4885
US-11116849-B2 Hydrogel-linked prodrugs releasing tagged drugs PTMS, PGLS, PAM HDAC4 649/4885HDAC1 608/4885HDAC11 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.